Do we think a fair estimate in value could be based on a multiplier of survival time compared to the existing medication Relivrio of 9 months and value of around $1B?
So if we get, say, 2 years survival the value of Monepantel (just for MND + minor side effects) should be around $2.6B
Based on SOI - 386,486,545
$2.60 = $1,004,865,017 MC
$5.20 = $2,009,730,034 MC
Ann: Investor webinar - Phase 1 MND Study Top-Line Results, page-65
-
- There are more pages in this discussion • 145 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add PAA (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
21.0¢ |
Change
0.000(0.00%) |
Mkt cap ! $83.14M | |||
| Open | High | Low | Value | Volume |
| 21.5¢ | 21.5¢ | 21.0¢ | $109.7K | 513.3K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 7 | 281695 | 20.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 21.0¢ | 27964 | 1 |
View Market Depth
| Last trade - 16.10pm 25/06/2024 (20 minute delay) ? |
| PAA (ASX) Chart |